VivoSeq
Other

Allogeneic Hematopoietic Cell Transplant

0

Pipeline Programs↗

9

Active Trials↗

3

Companies Involved↗

Allogeneic Hematopoietic Cell Transplant is an early-stage landscape with 0 programs across 3 companies. The most active players are Astellas, Novartis, Vor Biopharma.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalV

Vor Biopharma

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

30

clinical trials

Completed10 · 33%
Terminated9 · 30%
Recruiting7 · 23%
Active, not recruiting2 · 7%
Unknown status1 · 3%
Withdrawn1 · 3%

Clinical Trials

Trial Activity

30 trials

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Recruiting·UUniversity of Nebraska·Phase 2·NCT06799195·126 enrolled
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05873205·12 enrolled
Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
Recruiting·—·Phase 1·NCT04332341·20 enrolled
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
Recruiting·—·Phase 2·NCT05501756·60 enrolled
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Recruiting·UUniversity of Liege·Phase 2·NCT03852407·114 enrolled
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Recruiting·WWashington University School of Medicine·Phase 1/2·NCT04742634·209 enrolled
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Recruiting·National Cancer Institute (NCI)·Phase 1/2·NCT05327023·430 enrolled
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
Active, not recruiting·JJohns Hopkins All Children's Hospital·Phase 1·NCT03843528·15 enrolled
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03663933·71 enrolled
NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders
Completed·RRoswell Park Cancer Institute·Phase 2·NCT00053989·41 enrolled
Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Completed·Astellas logoAstellas·Phase 2·NCT00285259·112 enrolled
A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant
Completed·Astellas logoAstellas·Phase 2·NCT01903928·9 enrolled
Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
Completed·AAlloVir·Phase 2/3·NCT04693637·26 enrolled
Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
Completed·Novartis logoNovartis·Phase 4·NCT00654589·75 enrolled
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT02342613·32 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)